AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tecovirimat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 5291 | 869572-92-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Tecovirimat targets and inhibits the activity of the orthopoxvirus VP37 protein (encoded by and highly conserved in all members of the orthopoxvirus genus) and blocks its interaction with cellular Rab9 GTPase and TIP47, which prevents the formation of egress-competent enveloped virions necessary for cell-to-cell and long-range dissemination of virus.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.20 | g | O |
| 0.40 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,GSK3B,ITK,MAPK10,MAPK7,PDK1,PDK4,PDPK1,PIK3CB,PRKDC,STK33,TEK,TTK | 23 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 13, 2018 | FDA | SIGA TECHNOLOGIES | |
| Jan. 6, 2022 | EMA | SIGA TECHNOLOGIES NETHERLANDS B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 99.62 | 70.78 | 59 | 257 | 638276 | 41982743 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 82.79 | 76.55 | 49 | 238 | 1500136 | 109088876 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AX24 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| FDA MoA | N0000182140 | Cytochrome P450 2C19 Inhibitors |
| FDA MoA | N0000187062 | Cytochrome P450 2C8 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190118 | Cytochrome P450 3A Inducers |
| FDA EPC | N0000193857 | Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
Related Drugs by ATC class:
J05AX Other antivirals 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Smallpox | indication | 67924001 | DOID:8736 |
| Cowpox | indication | 70090004 | DOID:8956 |
| Monkeypox | indication | 359814004 | DOID:3292 |
| Complications due to replication of vaccinia virus following vaccination against smallpox | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.13 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 200MG/20ML (10MG/ML) | TPOXX | SIGA TECHNOLOGIES | N214518 | May 18, 2022 | RX | SOLUTION | INTRAVENOUS | 9907859 | Aug. 2, 2031 | TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG |
| 200MG | TPOXX | SIGA TECHNOLOGIES | N208627 | July 13, 2018 | RX | CAPSULE | ORAL | 7737168 | Sept. 4, 2031 | TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG |
| 200MG/20ML (10MG/ML) | TPOXX | SIGA TECHNOLOGIES | N214518 | May 18, 2022 | RX | SOLUTION | INTRAVENOUS | 7737168 | Sept. 4, 2031 | TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG |
| 200MG | TPOXX | SIGA TECHNOLOGIES | N208627 | July 13, 2018 | RX | CAPSULE | ORAL | 11890270 | Aug. 8, 2032 | TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Envelope protein F13 | Viral envelope protein | INHIBITOR | EC50 | 7.38 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| F925RR824R | UNII |
| 1162664-19-8 | SECONDARY_CAS_RN |
| 4039493 | VANDF |
| C2713595 | UMLSCUI |
| CHEBI:749735 | CHEBI |
| A1ICJ | PDB_CHEM_ID |
| CHEMBL1257073 | ChEMBL_ID |
| 16124688 | PUBCHEM_CID |
| DB12020 | DRUGBANK_ID |
| CHEMBL5315121 | ChEMBL_ID |
| D09390 | KEGG_DRUG |
| 9011 | INN_ID |
| C505045 | MESH_SUPPLEMENTAL_RECORD_UI |
| 40937011000001107 | SNOMEDCT_US |
| 772991002 | SNOMEDCT_US |
| 773289005 | SNOMEDCT_US |
| 40695 | MMSL |
| d09893 | MMSL |
| 017694 | NDDF |
| 2055104 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TPOXX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50072-010 | INJECTION, SOLUTION, CONCENTRATE | 10 mg | INTRAVENOUS | NDA | 29 sections |
| TPOXX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50072-200 | CAPSULE | 200 mg | ORAL | NDA | 29 sections |